BioSpace News Archive

Intelligent Bio Solutions Inc. today announced preliminary unaudited revenue results for fiscal Second Quarter and six months ended December 31, 2023.

RemeGen Co. Ltd., a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on February 4, has announced three major developments that will further the global fight against cancer and forge new paths in tumor treatments.

Zynex, Inc. announced The Healthcare Technology Report recognized Zynex as 9th amongst the Top 25 Medical Device Companies for 2024.

Synlogic, Inc. (Nasdaq: SYBX) announced today the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU).

NurExone Biologic Inc. is pleased to announce the initiation of the Orphan Drug Designation process with the European Medicines Agency for its groundbreaking ExoPTEN product, currently in development for patients with acute spinal cord injury.

Akebia Therapeutics®, Inc. granted five newly-hired employees options to purchase an aggregate of 856,950 shares of Akebia’s common stock on January 31, 2024, including an option to purchase 454,950 shares to Nik Grund, Akebia’s newly hired Chief Commercial Officer, and an option to purchase 336,000 shares to Richard Malabre, Akebia’s newly hired Chief Accounting Officer.

ORIC Pharmaceuticals, Inc. announced that on February 1, 2024, ORIC granted a total of 12,500 non-qualified stock options and 2,100 restricted stock units to two new non-executive employees who began their employment with ORIC in January 2024.

MacroGenics, Inc. announced that the Company’s management will participate in the following upcoming investor conference.

Azenta, Inc. announced the launch of the BioArc™ Ultra, a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance for large-scale sample management with the potential to forever change the landscape of biorepositories.

Revance Therapeutics, Inc. (RVNC) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J0589) for DAXXIFY®, indicated for the treatment of cervical dystonia in adults.